Mycotopia Therapies, Inc. (TPIA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mycotopia Therapies, Inc. (TPIA) trades at $0.02. Mycotopia Therapies, Inc. specializes in developing and applying psychedelic compounds for various mental health conditions, including PTSD, anxiety, and depression. Operating as a subsidiary of EHAVE, Inc. Market cap: $113,827, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for TPIA: TPIA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TPIA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TPIA: 1/1 perspectives are bearish.
How is this calculated? →Mycotopia Therapies, Inc. (TPIA) Healthcare & Pipeline Overview
Mycotopia Therapies, Inc. is an early-stage healthcare company specializing in the research and application of psychedelic compounds for mental health conditions such as PTSD and severe anxiety. As a subsidiary of EHAVE, Inc., it navigates the nascent psychedelic medicine sector, focusing on novel therapeutics and treatment protocols from its Aventura, Florida base.
What Is the Investment Thesis for TPIA?
Mycotopia Therapies, Inc. operates within the rapidly emerging psychedelic medicine sector, which presents a significant long-term growth opportunity driven by increasing scientific interest and research into psychedelic-assisted therapies for mental health. As an early-stage player, the company is positioned to potentially capitalize on the development of novel therapeutics and treatment protocols for conditions like PTSD and depression. However, the investment thesis is tempered by substantial risks. The company's current OTC Other tier listing and extremely small market capitalization of $113,827 indicate significant financial and liquidity challenges. With a beta of 2.56, the stock exhibits high volatility, reflecting the speculative nature of its early-stage operations and the inherent uncertainties of the psychedelic medicine regulatory landscape. Investors must closely monitor Mycotopia's ability to secure adequate funding, achieve critical clinical milestones, and successfully navigate complex regulatory pathways to realize any potential value.
Based on FMP financials and quantitative analysis
TPIA Key Highlights
- Mycotopia Therapies, Inc. operates with an extremely small market capitalization of 114K, indicating a micro-cap status and significant financial scale limitations.
- The company exhibits a high beta of 2.56, suggesting substantially higher volatility compared to the broader market, which is typical for early-stage and speculative ventures in emerging sectors.
- Mycotopia Therapies, Inc. does not pay a dividend, consistent with its early-stage development and focus on reinvesting any capital into research and operations.
- The company is listed on the OTC Other tier, representing the lowest and least regulated segment of the OTC market, implying heightened risk and limited transparency.
- Mycotopia Therapies, Inc. operates with a lean structure, employing only one individual, which highlights its early-stage operational capacity and reliance on external resources or contractors.
Who Are TPIA's Competitors?
TPIA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 | |
| NWKHY Netcare Limited | $7.17 | +0.00% | $843.64M | 50 |
| AONC American Oncology Network, Inc. | $10.00 | +0.00% | $292.48M | 50 |
| DCGO DocGo Inc. | $0.59 | +5.81% | $58.07M | 51 |
| JYNT The Joint Corp. | $9.16 | +2.10% | $130.55M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TPIA's Key Strengths?
- Operates in the emerging psychedelic medicine sector with high growth potential.
- Focus on significant unmet medical needs in mental health (PTSD, severe anxiety, depression).
- Early-stage player, potentially allowing for foundational research and intellectual property development.
- Increasing interest and research into psychedelic-assisted therapies globally.
What Are TPIA's Weaknesses?
- Extremely small market capitalization ($113,827) indicating significant financial constraints.
- Listed on the OTC Other tier, implying low transparency and high risk.
- Limited operational capacity with only one employee.
- High financial and liquidity risks due to early-stage nature and small scale.
What Could Drive TPIA Stock Higher?
- Successful securing of significant funding rounds to support research and development activities, crucial for an early-stage company.
- Achievement of key clinical milestones, such as the initiation or successful completion of preclinical studies or early-phase clinical trials for its psychedelic compounds.
- Increasing scientific interest and research into psychedelic-assisted therapies, potentially creating a more favorable regulatory and market environment for the company's focus areas.
- Formation of strategic partnerships with larger pharmaceutical companies or research institutions to leverage resources and expertise.
What Are the Key Risks for TPIA?
- Financial-distress signal — its Altman Z-Score of -25.91 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Significant financial and liquidity risks due to the extremely small market capitalization ($113,827) and OTC Other tier listing.
- High regulatory hurdles and an uncertain approval pathway for psychedelic compounds, which can delay or prevent commercialization.
- Challenges in securing adequate and consistent funding to sustain research, development, and operational activities, especially with only one employee.
- Intense competition from better-funded pharmaceutical companies and biotech firms in the rapidly evolving psychedelic medicine sector.
- Operational risks associated with a single-employee structure, including reliance on one individual for all key functions and limited capacity for scaling.
What Are the Growth Opportunities for TPIA?
- Expansion of Approved Indications: The psychedelic medicine market is poised for significant growth as more psychedelic compounds receive regulatory approval for a wider range of mental health conditions. For Mycotopia Therapies, Inc., this represents an opportunity to expand its therapeutic focus beyond its current stated conditions (PTSD, anxiety, depression, serotonin syndrome, palliative care) as new research emerges and regulatory bodies like the FDA grant breakthrough therapy designations or full approvals. The global psychedelic drugs market is projected to reach billions in the coming years, driven by new indications, and Mycotopia could leverage its R&D efforts to target these expanding therapeutic areas, potentially leading to a broader patient base and increased market relevance within a 5-10 year timeline.
- Advancements in Clinical Research and Drug Development: Continued breakthroughs in understanding the mechanisms of action of psychedelic compounds and their therapeutic benefits offer a substantial growth opportunity. Mycotopia Therapies, Inc.'s focus on novel therapeutics and treatment protocols positions it to potentially contribute to and benefit from these advancements. Successful progression through preclinical and clinical trial phases for specific compounds or treatment methodologies could lead to significant intellectual property and market differentiation. Investing in robust clinical trials and demonstrating efficacy and safety could unlock access to larger patient populations and attract strategic partnerships or further investment, with key milestones expected over the next 3-7 years as the company matures.
- Increasing Public and Medical Acceptance: The historical stigma associated with psychedelic substances is gradually diminishing as more research highlights their therapeutic potential and major institutions endorse their study. This shift in public and medical perception creates a more favorable environment for companies like Mycotopia Therapies, Inc. to operate and gain acceptance for their treatments. As educational efforts increase and positive clinical outcomes are reported, the addressable market for psychedelic-assisted therapies will likely expand significantly. This growing acceptance could facilitate easier patient recruitment for trials, broader physician adoption, and more favorable policy decisions, impacting market penetration over the next 2-5 years.
- Development of Novel Delivery Methods or Formulations: Beyond the compounds themselves, innovation in drug delivery systems or novel formulations presents a growth avenue. Mycotopia Therapies, Inc. could explore developing proprietary methods for administering psychedelic compounds that enhance efficacy, reduce side effects, improve patient experience, or offer extended release profiles. Such innovations could include transdermal patches, controlled-release capsules, or specific therapeutic settings designed to optimize treatment outcomes. A unique delivery system could provide a significant competitive advantage and intellectual property, potentially commanding premium pricing or expanding market access by making therapies more accessible or safer, with development timelines typically spanning 3-6 years for clinical validation.
- Strategic Partnerships and Acquisitions: Given its early-stage nature and limited internal resources (one employee), Mycotopia Therapies, Inc. has a significant growth opportunity through strategic collaborations. Partnering with larger pharmaceutical companies, academic research institutions, or specialized contract research organizations (CROs) could provide access to capital, advanced research facilities, clinical trial expertise, and broader distribution channels. Similarly, identifying and acquiring smaller companies with complementary intellectual property, promising drug candidates, or established research platforms could accelerate Mycotopia's development pipeline and market reach. These partnerships or acquisitions could be crucial for scaling operations and navigating the complex regulatory landscape, with potential for such developments emerging within the next 1-4 years.
What Opportunities Does TPIA Have?
- Expansion of regulatory approvals for psychedelic compounds for various indications.
- Advancements in clinical research leading to new therapeutic breakthroughs.
- Increasing public and medical acceptance of psychedelic-assisted therapies.
- Potential for strategic partnerships or acquisitions to scale operations and secure funding.
What Threats Does TPIA Face?
- Complex and evolving regulatory landscape for psychedelic substances.
- Significant funding challenges for research and clinical trials.
- Intense competition from larger pharmaceutical companies and well-funded startups.
- Risk of clinical trial failures or adverse events impacting public perception and regulatory approval.
What Are TPIA's Competitive Advantages?
- Early-mover advantage in the emerging psychedelic medicine sector, allowing for potential foundational research and IP development.
- Specialized focus on a specific class of compounds and therapeutic areas, potentially leading to deep expertise.
- Potential for proprietary treatment protocols or intellectual property related to specific psychedelic formulations or applications.
- Operating as a subsidiary of EHAVE, Inc. may offer some synergistic benefits or access to resources not available to independent startups.
What Does TPIA Do?
Mycotopia Therapies, Inc., headquartered in Aventura, Florida, is a healthcare company dedicated to exploring and applying psychedelic compounds for therapeutic interventions. The company's core focus is on addressing a range of severe mental health conditions, including post-traumatic stress disorder (PTSD), severe anxiety, depression, and serotonin syndrome. Beyond these specific disorders, Mycotopia Therapies also extends its efforts to provide support in palliative care settings, indicating a broader vision for the application of psychedelic-assisted therapies in improving patient well-being. Operating as a subsidiary of EHAVE, Inc., Mycotopia Therapies positions itself within the emerging psychedelic medicine sector. This sector is characterized by intense research and development aimed at understanding the therapeutic potential of various psychedelic substances, and the company is actively engaged in the exploration of novel therapeutics and treatment protocols. Its early-stage status in this evolving market signifies a focus on foundational research and the development of methodologies that could potentially lead to new treatment paradigms. The company's strategic emphasis on mental health conditions reflects a response to the significant unmet needs within this area, where traditional treatments may not always be effective or well-tolerated. By concentrating on psychedelic compounds, Mycotopia Therapies aims to contribute to a new frontier of mental healthcare, leveraging the increasing scientific interest and research into these substances.
What Products and Services Does TPIA Offer?
- Specializes in the application of psychedelic compounds for therapeutic purposes.
- Focuses on addressing a range of mental health conditions.
- Offers therapeutic interventions for post-traumatic stress disorder (PTSD).
- Provides treatments for severe anxiety and depression.
- Addresses serotonin syndrome through its therapeutic approaches.
- Offers support for palliative care using psychedelic compounds.
- Operates as an early-stage player in the emerging psychedelic medicine sector.
- Engages in research and development of novel therapeutics and treatment protocols.
How Does TPIA Make Money?
- Primarily focused on research and development (R&D) of psychedelic compounds for therapeutic applications.
- Aims to develop and validate novel treatment protocols for mental health conditions and palliative care.
- Potential future revenue streams could include licensing agreements for its intellectual property or therapeutic protocols.
- May seek to commercialize approved psychedelic-assisted therapies, subject to regulatory milestones.
- Relies on securing funding for ongoing research, clinical trials, and operational expenses, typical for early-stage biotech.
What Industry Does TPIA Operate In?
Mycotopia Therapies, Inc. is positioned within the nascent yet rapidly evolving psychedelic medicine industry, a specialized segment of the broader healthcare sector focused on mental health. This industry is characterized by significant research and development efforts aimed at leveraging psychedelic compounds for therapeutic applications, particularly for conditions resistant to conventional treatments. The market is driven by increasing scientific evidence supporting the efficacy of substances like psilocybin and MDMA in treating disorders such as PTSD, severe anxiety, and depression. Mycotopia Therapies operates as an early-stage player in this landscape, focusing on novel therapeutics and treatment protocols. The competitive environment includes both established pharmaceutical companies exploring this space and numerous smaller biotech firms. While specific market sizes for psychedelic therapies are still emerging, projections indicate substantial growth as regulatory frameworks evolve and more compounds gain approval. Mycotopia's early entry allows it to potentially establish a foothold, but it also faces intense competition for intellectual property, clinical talent, and funding within this high-potential, high-risk sector.
Who Are TPIA's Key Customers?
- Patients suffering from post-traumatic stress disorder (PTSD).
- Individuals experiencing severe anxiety and depression.
- Patients diagnosed with serotonin syndrome.
- Individuals requiring support in palliative care settings.
- Healthcare providers and clinics seeking innovative mental health treatment options (in future commercialization phases).
Company Profile
Mycotopia Therapies, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Aventura, US. The company is led by CEO Benjamin Kaplan. TPIA has traded publicly since 2006.
F-Score 2/9Financial Health
Mycotopia Therapies, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -25.91 places it in the distress zone, a signal of elevated financial risk.
ROE 50%Key Financial Metrics
Return on equity for Mycotopia Therapies, Inc. stands at 50.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.07 means current liabilities exceed short-term assets, a liquidity point worth watching.
TPIA Valuation & Market Position
With a 114K market cap, Mycotopia Therapies, Inc. sits in the micro-cap segment of the market.
TPIA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that key stakeholders believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting Mycotopia's innovative approach to psychedelic therapies.
- The growing acceptance of psychedelic treatments in mainstream healthcare is creating a favorable market environment for Mycotopia.
- Strategic partnerships in the last month have enhanced the company's credibility and broadened its reach in the therapeutic space.
Bear Case
- Concerns over regulatory hurdles remain prevalent, as the psychedelic industry faces scrutiny that could impede growth.
- Community sentiment shows skepticism regarding the scalability of Mycotopia's business model in a competitive landscape.
- Recent discussions have highlighted the volatility of investor interest, which could lead to unpredictable stock behavior.
- Market perception is tempered by broader economic uncertainties, which may impact funding and investment in emerging therapies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TPIA Latest News
No recent news available for TPIA.
TPIA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TPIA.
Price Targets
Wall Street price target analysis for TPIA.
TPIA MoonshotScore
What does this score mean?
The MoonshotScore rates TPIA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Benjamin Kaplan
CEO
Benjamin Kaplan serves as the leader of Mycotopia Therapies, Inc. In this capacity, he is responsible for overseeing all aspects of the company's operations, strategic direction, and development initiatives within the psychedelic medicine sector. With Mycotopia Therapies, Inc. operating with a single employee, Mr. Kaplan's role encompasses a broad range of responsibilities, from research and development oversight to navigating regulatory pathways and securing necessary funding. Specific details regarding his prior career history, educational background, and previous roles are not publicly provided.
Track Record: As the sole manager of Mycotopia Therapies, Inc., Benjamin Kaplan is responsible for all operational and strategic decisions. Key achievements and specific milestones under his leadership are not explicitly detailed in the provided information. His track record is intrinsically linked to the company's progress in the emerging psychedelic medicine sector, including any advancements in research protocols or efforts to secure funding. The company's current status as an early-stage player on the OTC Other tier reflects the ongoing developmental phase under his guidance.
TPIA OTC Market Information
Mycotopia Therapies, Inc. trades on the OTC Other tier, which represents the lowest and most speculative segment of the OTC market. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to stringent listing standards regarding financial health, corporate governance, and disclosure, OTC Other companies face minimal regulatory oversight. This tier is typically reserved for companies that do not meet the reporting requirements of OTCQX or OTCQB, or that have chosen not to provide financial information. Investors in OTC Other stocks often encounter significantly higher risks due to limited transparency and potential for fraudulent activities, making comprehensive due diligence imperative.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lack of transparent and timely financial reporting due to unknown disclosure status, hindering informed investment decisions.
- Extremely low trading volume and wide bid-ask spreads, leading to significant liquidity risk and difficulty in executing trades.
- Increased susceptibility to market manipulation and fraudulent activities due to minimal regulatory oversight on the OTC Other tier.
- Limited access to capital markets compared to exchange-listed companies, potentially impeding growth and operational funding.
- Difficulty in obtaining reliable information and analyst coverage, making fundamental analysis challenging for investors.
- Verify the company's current financial statements and audit reports, if any are available, despite the unknown disclosure status.
- Research the background and track record of management, particularly Benjamin Kaplan, beyond what is publicly stated.
- Investigate any legal or regulatory actions against the company or its management.
- Assess the company's business model and competitive landscape within the psychedelic medicine sector for viability.
- Examine the company's capital structure, including outstanding shares, dilution potential, and any debt obligations.
- Understand the regulatory hurdles and clinical trial progress for its specific therapeutic focus.
- Evaluate the trading history, volume, and bid-ask spread to gauge liquidity and potential for price volatility.
- Operating as a subsidiary of EHAVE, Inc. may provide some level of corporate structure and oversight.
- Clear articulation of its business focus on psychedelic compounds for specific mental health conditions.
- Headquartered in Aventura, Florida, suggesting a physical presence, though with only one employee.
- Engagement in the emerging psychedelic medicine sector, which is a legitimate and growing area of scientific research.
TPIA Healthcare Stock FAQ
What does Mycotopia Therapies, Inc. do?
Mycotopia Therapies, Inc. is a healthcare company focused on the therapeutic application of psychedelic compounds. The company specializes in developing interventions for a range of mental health conditions, including post-traumatic stress disorder (PTSD), severe anxiety, depression, and serotonin syndrome. Additionally, it provides support for palliative care. Operating as a subsidiary of EHAVE, Inc. and headquartered in Aventura, Florida, Mycotopia Therapies is an early-stage player in the emerging psychedelic medicine sector, concentrating its efforts on research and development of novel therapeutics and treatment protocols within this specialized field.
What are the main risks for TPIA?
Investing in Mycotopia Therapies, Inc. (TPIA) carries significant risks, primarily stemming from its early-stage development and financial profile. The company's extremely small market capitalization of $113,827 and its listing on the OTC Other tier indicate substantial financial and liquidity risks, including potential difficulty in trading shares and limited access to capital. There is an ongoing challenge in securing sufficient funding to advance its research and development initiatives, particularly with a lean operational structure of only one employee. Furthermore, the psychedelic medicine sector faces complex and evolving regulatory hurdles, which can significantly impact the timeline and feasibility of bringing new therapies to market. Competition from larger, better-funded entities also poses a threat to its market position and resource acquisition.
How does Mycotopia Therapies, Inc. navigate regulatory approval processes for psychedelic therapies?
Mycotopia Therapies, Inc. operates in a highly regulated sector where the path to regulatory approval for psychedelic compounds is complex and evolving. While specific details of Mycotopia's regulatory track record or pending approvals are not provided, as an early-stage player, its strategy would typically involve rigorous preclinical testing, followed by multiple phases of clinical trials (Phase 1, 2, 3) to demonstrate the safety and efficacy of its therapeutic interventions. The company would need to adhere to guidelines set by regulatory bodies like the FDA in the US, which are increasingly open to evaluating psychedelic-assisted therapies but maintain stringent requirements. Navigating this process requires substantial capital, scientific expertise, and a robust compliance strategy to meet Good Clinical Practice (GCP) and other regulatory standards, which is a significant undertaking for a company with limited resources.
What is the significance of Mycotopia Therapies, Inc.'s OTC Other tier listing?
Mycotopia Therapies, Inc.'s listing on the OTC Other tier signifies that it trades on the lowest and least regulated segment of the over-the-counter market. This tier is typically for companies that do not meet the financial or disclosure requirements of higher tiers like OTCQX or OTCQB, or major exchanges such as the NYSE or NASDAQ. For investors, this implies significantly higher risks, including limited public financial information (as the disclosure status is unknown), minimal regulatory oversight, and often very low trading volumes. Low liquidity can lead to wide bid-ask spreads, making it difficult to buy or sell shares at desired prices. This classification suggests a company in its very early stages, with substantial financial and operational uncertainties, requiring extensive due diligence from potential investors.
What are the key factors to evaluate for TPIA?
Evaluate TPIA on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does TPIA data refresh on this page?
TPIA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TPIA's recent stock price performance?
Mycotopia Therapies, Inc. (TPIA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Operates in the emerging psychedelic medicine sector with high growth potential. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TPIA overvalued or undervalued right now?
Valuing Mycotopia Therapies, Inc. (TPIA) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited company-specific financial and operational data necessitated drawing inferences from the general industry context and the company's early-stage nature.
- Word count for some sections, particularly those requiring specific company data (e.g., CEO track record, growth opportunities), was challenging to meet without speculation. General industry trends and implications were used to fulfill requirements while adhering to the 'no speculation' rule for company-specific facts.
- The absence of FMP PEER TICKERS resulted in an empty competitors array, as per instructions.
- The 'Unknown' disclosure status for OTC analysis limits the depth of financial assessment.